Oya KAYACAN, Fatma ÇİFTCİ, Elif SEN, Nalan DEMİR

Hastalarımız Pnömokok Asısını Biliyor Mu?

Amaç: Günümüzde etkinliği kanıtlanmasına rağmen pnömokok asısıyla asılanma oranının oldukça düsük olduğunu görüyoruz. Asılanma davranısını etkileyen faktörlerin aydınlatılması asılanmayı arttırmak için çözüm yollarına ısık tutabilir. Bu amaçla hastaların pnömokok asısı ile asılanma oranları ve asılanma davranısını etkileyen faktörler değerlendirildi. Gereç ve Yöntem: Ekim 2011 ve Ocak 2012 tarihleri arasında Göğüs Hastalıkları polikliniğine basvuran tüm hastalara yazılı bir anket uygulandı. Bulgular: Polikliniğe basvuran 1251 (671 kadın, 580 erkek) hasta arastırmaya dahil oldu. Pnömokok asısı endikasyonu olan 766 hastanın %9.9' u asılandığını belirtti. Yasın artması ile asılanma oranı artıyordu. (OR, 2,71; CI, 1,09-5,22; p

What do Patients Know About Pneumococcal Vaccine?

Aim: Despite its proven efficacy, the rate of antipneumococcal vaccination remains considerably low. Determination of factors affecting vaccination behavior may contribute to efforts aimed at boosting vaccination rates. We therefore aimed to investigate the anti-pneumococcal vaccination rates and potential factors affecting vaccination behavior among patients presenting to chest disease department. Material and Method: A written questionnaire was applied to all patients who presented to Chest Diseases Department between October 2011 and January 2012. Results: A total of 1251 patients (671 women, 580 men) were enrolled. Among 766 participants who had any indication for anti-pneumococcal vaccination, 9.9% stated that they had been vaccinated. The rate of vaccination increased with increasing age (OR, 2.71; CI, 1.09-5.22; p

PDF

___

1. Centers for Disease Control and Prevention. CDC framework for preventing infectious diseases. Sustaining the Essentials and Innovating for the Future, Atlanta, Georgia, 2011. Available at: http://www.cdc.gov
2. Janoff EN, Musher DM. Streptococcus pneumonia In: Bennet JE, Dolin R, Blaser MJ., editors. Principles and Practice of Infectious Diseases. 8th ed. Philadelphia: Elsevier, 2015:2310-2327.
3. Drijkoningen J, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 2014; 20: 45-51
4. Recommended Adult Immunization Schedule. United States-2016. Available from: http://www.cdc.gov/vaccines/schedules/ downloads/adult/adult-combined schedule. pdf.
5. Birinci Basamak Sağlık Hizmetlerinde Çalışan Hekimler için Yaşlı Sağlığı Tanı ve Tedavi Rehberi 2010. Sağlık Bakanlığı Temel Sağlık Hizmetleri Genel Müdürlüğü. Available from: http://sbu.saglik.gov.tr/ Ekutuphane/ kitaplar/t3.pdf
6. Centers for Disease Control and Prevention. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >=65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. September 19, 2014 / 63(37);822-825. Available from : http://www.cdc.gov
7. Domínguez A, Izquierdo C, Salleras L, Ruiz L, Sousa D, et al. Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly. Eur Resp J 2010; 36:608-614.
8. Naito T, Matsuda N, Tanei M, et al. Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the great East Japan earthquake J Infect Chemother 2014;20: 450-453.
9. Poethko-Müller C, Schmitz R. Vaccination coverage in German adults: results of the German health interview and examination survey for adults (DEGS1). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2013; 56: 845-857.
10. Aka Aktürk Ü, Görek Dilektaşlı A, Şengül A, et al. Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease. Balkan Med J 2017;34:206-211.
11. Alici DE, Sayiner A, Unal S.Barriers to adult immunization and solutions: Personalized approaches. Hum Vaccin Immunother 2017;13:213-215.
12. Özsu S, Uçar E, Arslan Y, ve ark. The frequency of influenza and pneumococcal vaccination in COPD. Solunum 2011; 13:21-25.
13. Erer OF, Karadeniz G, Gazibaba D, ve ark. Immunization in the chronic obstructive pulmonary disease: Can we have really done it? İzmir Göğüs Hastanesi Dergisi 2013; 27:31-40.
14. Vila-Corcoles A, Ochoa-Gondar O, Guzmán JA, et al; EPIVAC Study Group. Effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in people 60 years or older. BMC Infect Dis 2010;10:73.
15. Williams WW, Lu PJ, O'Halloran A, et al. Surveillance of Vaccination Coverage among Adult Populations - United States, 2015. MMWR Surveill Summ 2017;66:1- 28.
16. Eilers R, de Melker HE, Veldwijk J, Krabbe PFM. Vaccine preferences and acceptance of older adults. Vaccine 2017;35:2823-2830.
17. Giese C, Mereckiene J, Danis K, et al. Low vaccination coverage for seasonal influenza and pneumococcal disease among adults at-risk and health care workers in Ireland, 2013: The key role of GPs in recommending vaccination. . Vaccine 2016;34:3657-3662.
18. Shea KM, Edelsberg J, Weycker D, et al. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 2014;1:ofu024.
19. van Hoek AJ, Andrews N, Waight PA, et al. The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012;65:17-24.
20. Seminog OO, Goldacre MJ. Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med 2013;30:1412-1419.
21. de Waure C, Quaranta G, Ianuale C, et al. Knowledge, attitudes and behaviors of the Italian population towards Neisseria meningitidis, Streptococcus pneumoniae and HPV diseases and vaccinations: A crosssectional multicentre study. Public Health 2016;141:136-142.
22. Lu PJ, O'Halloran A, Kennedy ED, et al. Awareness among adults of vaccinepreventable diseases and recommended vaccinations, United States, 2015. Vaccine 2017;35:3104-3115.
23. Kim S, Hughes CA, Sadowski CA. A review of acute care interventions to improve inpatient pneumococcal vaccination. Prev Med 2014;67:119-127.
24. Satman I, Akalin S, Cakir B, Altinel S; diaVAX Study Group. The effect of physicians' awareness on influenza and pneumococcal vaccination rates and correlates of vaccination in patients with diabetes in Turkey: an epidemiological Study "diaVAX". Hum Vaccin Immunother 2013;9:2618-2626.
25. Nowalk MP, Zimmerman RK, Shen S, Jewell IK, Raymund M. Barriers to pneumococcal and influenza vaccination in older community-dwelling adults (2000-2001). J Am Geriatr Soc 2004; 52:25-30.
26. Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med 2008; 121:28-35.
27. Schneeberg A, Bettinger JA, McNeil S, et al. Knowledge, attitudes, beliefs and behaviours of older adults about pneumococcal immunization, a Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) investigation. BMC Public Health 2014;14: 442.
28. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease. Thorax 2015;70: 984-989.
29. Cimen P, Unlu M, Kirakli C, et al. Should Patients with copd be vaccinated? Respir Care 2015;60:239-243.